Polo-like Kinase 4: A Multifaceted Marker Linking Tumor Aggressiveness and Unfavorable Prognosis, and Insights into Therapeutic Strategies.
Youngtaek KimJoon Yeon HwangDong Kwon KimKwangmin NaSeul LeeSujeong BaekSeong-San KangSeung Min YangMi Hyun KimHeekyung HanChai Young LeeYu Jin HanMin Hee HongJii Bum LeeSun Min LimByoung Chul ChoYoungjoon ParkKyoung-Ho PyoPublished in: Cancers (2023)
(1) Background: This study investigated whether polo-like kinase 4 (PLK4) is a suitable therapeutic target or biomarker for lung adenocarcinoma (LUAD). (2) Methods: We acquired LUAD data from The Cancer Genome Atlas (TCGA) database through the UCSC Xena data portal. Gene expression, clinical, survival, and mutation data from multiple samples were analyzed. Gene enrichment analysis, unsupervised clustering of PLK4 -related pathways, and differential gene expression analyses were performed. Additionally, correlations, t -tests, survival analyses, and statistical analyses were performed. (3) Results: PLK4 expression was higher in LUAD tissues than in normal tissues and was associated with poor prognosis for both overall and progression-free survival in LUAD. PLK4 was highly correlated with cell-proliferation-related pathways using Gene Ontology (GO) biological process terms. PLK4 expression and pathways that were highly correlated with PLK4 expression levels were upregulated in patients with LUAD with the TP53 mutation. (4) Conclusions: PLK4 expression affects the survival of patients with LUAD and is a potential therapeutic target for LUAD with TP53 mutations.
Keyphrases
- poor prognosis
- gene expression
- free survival
- long non coding rna
- cell proliferation
- electronic health record
- dna methylation
- genome wide
- machine learning
- binding protein
- big data
- emergency department
- single cell
- young adults
- cell cycle
- high resolution
- signaling pathway
- rna seq
- artificial intelligence
- pi k akt
- risk assessment
- adverse drug
- drug induced
- genome wide identification
- childhood cancer